+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nordic Regulatory Affairs Market Size, Share & Trends Analysis Report by Services (Regulatory Consulting, Legal Representation), Category, Type, Company Size, Product Stage, Indication, End-Use, Country with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 120 Pages
  • February 2025
  • Region: Denmark, Finland, Iceland, Norway, Sweden
  • Grand View Research
  • ID: 6056012
Description Jump to:
The Nordic Regulatory Affairs Market was valued at USD 586.3 million in 2024, and is projected to reach USD 890.7 million by 2030, rising at a CAGR of 7.25%. An increase in R&D activities in countries such as Denmark and Norway, drug pipeline, and clinical trial applications are some of the key factors expected to drive the market.

Denmark is the hub of R&D activities in Europe. The country is known for its long tradition for collaborative R&D and the fastest approval of clinical trials makes it a preferred destination to perform drug discovery and development. Denmark also has the largest commercial drug-development pipeline in Europe. Thus, the urge for a faster drug approval process is one of the key factors expected to drive the market in the country.

In Sweden, as stated by the SwedenBIO, around 148 companies have 420 drug development projects; an increase by 51 projects compared to 2016. In addition, around 6% of the total exports from Sweden are related to pharmaceuticals. Hence, this is projected to create demand for regulatory affairs services in the country.

The ongoing COVID-19 pandemic is expected to create the need for regulatory affairs in the Nordic countries. Countries such as Sweden and Denmark, which are the hub of clinical trials, are expected to witness an increase in demand for regulatory services as many of the trials are put on hold. In addition to this, due to COVID-19, a significant number of vaccines and drugs are in the development stage, which requires faster approval. This is possible only through clearance by regulatory bodies. Thus, the need for regulatory affairs is expected to increase in the Nordic countries.

Nordic Regulatory Affairs Market Report Highlights

  • By service, the regulatory writing and publishing segment led the market in 2024, owing to an increase in the outsourcing of selected regulatory functions by major life sciences companies.
  • Based on category, the biologics segment is projected to witness considerable growth during the forecast year, attributed to factors such as increasing R&D investments from pharmaceutical and biotechnology firms.
  • Denmark regulatory affairs market accounted for the largest revenue share of 34.13% in 2024, owing to its strong pharmaceutical and biotechnology sector, supported by a well-established regulatory framework.
  • Changing regulatory landscape, increasing need for companies to focus on core business activities, and economic and competitive pressures are the main factors responsible for the market growth.

This report addresses:

  • Market intelligence to enable effective decision-making.
  • Market estimates and forecasts from 2018 to 2030.
  • Growth opportunities and trend analyses.
  • Segment and regional revenue forecasts for market assessment.
  • Competition strategy and market share analysis.
  • Product innovation listings for you to stay ahead of the curve.
  • COVID-19's impact and how to sustain in this fast-evolving market.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Type Segment
1.2.2. Services Segment
1.2.3. Category Segment
1.2.4. Indication Segment
1.2.5. Product Stage Segment
1.2.6. Company Size Segment
1.2.7. Indication Segment
1.2.8. End-use Segment
1.3. Information analysis
1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. Nordic Regulatory Affairs Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Changing Regulatory Landscape
3.2.1.2. Life Science Companies Focusing on Their Core Competencies
3.2.1.3. Economic and Competitive Pressures
3.2.1.4. Demand For the Faster Approval Process for Breakthrough Drugs and Devices
3.2.1.5. Growth in Emerging Areas Such as Personalized Medicine, Biosimilars, And Orphan Drugs
3.2.2. Market restraint analysis
3.2.2.1. Risk Associated with Data Security
3.2.2.2. Monitoring Issues and Lack of Standardization
3.3. Regulatory Affairs Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Nordic Regulatory Affairs Market: Services Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Nordic Regulatory Affairs Market Services Movement Analysis
4.3. Nordic Regulatory Affairs Market Size & Trend Analysis, by Services, 2018 to 2030 (USD Million)
4.4. Regulatory Consulting
4.4.1. Regulatory consulting market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Legal Representation
4.5.1. Legal representation market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Regulatory Writing & Publishing
4.6.1. Regulatory writing & publishing market estimates and forecasts, 2018 to 2030 (USD Million)
4.6.1.1. Writing
4.6.1.1.1. Writing market estimates and forecasts, 2018 to 2030 (USD Million)
4.6.1.2. Publishing
4.6.1.2.1. Publishing market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. Product Registration & Clinical Trial Applications
4.7.1. Product registration & clinical trial applications market estimates and forecasts, 2018 to 2030 (USD Million)
4.8. Other Services
4.8.1. Other services market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Nordic Regulatory Affairs Market: Category Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Nordic Regulatory Affairs Market Category Movement Analysis
5.3. Nordic Regulatory Affairs Market Size & Trend Analysis, by Category, 2018 to 2030 (USD Million)
5.4. Drugs
5.4.1. Drugs market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2. Innovators
5.4.2.1. Innovators market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2.2. Preclinical
5.4.2.2.1. Preclinical market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2.3. Clinical
5.4.2.3.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2.4. Pre-Market Approval (PMA)
5.4.2.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.3. Generics
5.4.3.1. Generics market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.3.2. Preclinical
5.4.3.2.1. Preclinical market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.3.3. Clinical
5.4.3.3.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.3.4. Pre-Market Approval (PMA)
5.4.3.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Biologics
5.5.1. Biologics market estimates and forecasts, 2018 to 2030 (USD Million)
5.5.2. Biotech
5.5.2.1. Biotech market estimates and forecasts, 2018 to 2030 (USD Million)
5.5.2.2. Preclinical
5.5.2.2.1. Preclinical market estimates and forecasts, 2018 to 2030 (USD Million)
5.5.2.3. Clinical
5.5.2.3.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
5.5.2.4. Pre-Market Approval (PMA)
5.5.2.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 to 2030 (USD Million)
5.5.3. ATMP
5.5.3.1. ATMP market estimates and forecasts, 2018 to 2030 (USD Million)
5.5.3.2. Preclinical
5.5.3.2.1. Preclinical market estimates and forecasts, 2018 to 2030 (USD Million)
5.5.3.3. Clinical
5.5.3.3.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
5.5.3.4. Pre-Market Approval (PMA)
5.5.3.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Biosimilars
5.6.1. Biosimilars market estimates and forecasts, 2018 to 2030 (USD Million)
5.6.1.1. Preclinical
5.6.1.1.1. Preclinical market estimates and forecasts, 2018 to 2030 (USD Million)
5.6.1.2. Clinical
5.6.1.2.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
5.6.1.3. Pre-Market Approval (PMA)
5.6.1.3.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Medical Devices
5.7.1. Medical devices market estimates and forecasts, 2018 to 2030 (USD Million)
5.7.2. Diagnostics
5.7.2.1. Diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
5.7.2.2. Preclinical
5.7.2.2.1. Preclinical market estimates and forecasts, 2018 to 2030 (USD Million)
5.7.2.3. Clinical
5.7.2.3.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
5.7.2.4. Pre-Market Approval (PMA)
5.7.2.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 to 2030 (USD Million)
5.7.3. Therapeutics
5.7.3.1. Therapeutics market estimates and forecasts, 2018 to 2030 (USD Million)
5.7.3.2. Preclinical
5.7.3.2.1. Preclinical market estimates and forecasts, 2018 to 2030 (USD Million)
5.7.3.3. Clinical
5.7.3.3.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
5.7.3.4. Pre-Market Approval (PMA)
5.7.3.4.1. Pre-Market Approval (PMA) market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Nordic Regulatory affairs market: Indication Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Nordic Regulatory Affairs Market Indication Movement Analysis
6.3. Nordic Regulatory Affairs Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
6.4. Oncology
6.4.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Neurology
6.5.1. Neurology market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Cardiology
6.6.1. Cardiology market estimates and forecasts, 2018 to 2030 (USD Million)
6.7. Immunology
6.7.1. Immunology market estimates and forecasts, 2018 to 2030 (USD Million)
6.8. Others
6.8.1.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Nordic Regulatory Affairs Market: Product Stage Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Nordic Regulatory Affairs Market Product Stage Movement Analysis
7.3. Nordic Regulatory Affairs Market Size & Trend Analysis, by Product Stage, 2018 to 2030 (USD Million)
7.4. Preclinical
7.4.1. Preclinical market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Clinical studies
7.5.1. Clinical studies market estimates and forecasts, 2018 to 2030 (USD Million)
7.6. Pre-Market Approval (PMA)
7.6.1. PMA market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Nordic Regulatory Affairs Market: Type Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Nordic Regulatory Affairs Market Type Movement Analysis
8.3. Nordic Regulatory Affairs Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
8.4. In-house
8.4.1. In-house market estimates and forecasts, 2018 to 2030 (USD Million)
8.5. Outsourced
8.5.1. Outsourced market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 9. Nordic Regulatory Affairs Market: Company Size Estimates & Trend Analysis
9.2. Nordic Regulatory Affairs Market Company Size Movement Analysis
9.3. Nordic Regulatory Affairs Market Size & Trend Analysis, by Company Size, 2018 to 2030 (USD Million)
9.4. Small
9.4.1. Small market estimates and forecasts, 2018 to 2030 (USD Million)
9.5. Medium
9.5.1. Medium market estimates and forecasts, 2018 to 2030 (USD Million)
9.6. Large
9.6.1. Large market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 10. Nordic Regulatory Affairs Market: End-use Estimates & Trend Analysis
10.1. Segment Dashboard
10.2. Nordic Regulatory Affairs Market End-use Movement Analysis
10.3. Nordic Regulatory Affairs Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
10.4. Medical Device Companies
10.4.1. Medical device companies market estimates and forecasts, 2018 to 2030 (USD Million)
10.5. Pharmaceutical Companies
10.5.1. Pharmaceutical companies market estimates and forecasts, 2018 to 2030 (USD Million)
10.6. Biotechnology Companies
10.6.1. Biotechnology companies market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 11. Nordic Regulatory Affairs Market: Country Estimates & Trend Analysis
11.1. Country Market Share Analysis, 2024 & 2030
11.2. Country Market Dashboard
11.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
11.4. Denmark
11.4.1. Key country dynamics
11.4.2. Competitive scenario
11.4.3. Regulatory Scenario
11.4.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
11.5. Norway
11.5.1. Key country dynamics
11.5.2. Competitive scenario
11.5.3. Regulatory Scenario
11.5.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
11.6. Sweden
11.6.1. Key country dynamics
11.6.2. Competitive scenario
11.6.3. Regulatory Scenario
11.6.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
11.7. Finland
11.7.1. Key country dynamics
11.7.2. Competitive scenario
11.7.3. Regulatory Scenario
11.7.4. Finland market estimates and forecasts, 2018 to 2030 (USD Million)
11.8. Iceland
11.8.1. Key country dynamics
11.8.2. Competitive scenario
11.8.3. Regulatory Scenario
11.8.4. Iceland market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 12. Competitive Landscape
12.1. Company Categorization
12.2. Company Market Share/Assessment Analysis, 2024
12.3. Company Profiles
12.3.1. Pharma Assist Sweden AB
12.3.1.1. Company overview
12.3.1.2. Financial performance
12.3.1.3. Product benchmarking
12.3.1.4. Strategic initiatives
12.3.2. Genpact
12.3.2.1. Company overview
12.3.2.2. Financial performance
12.3.2.3. Product benchmarking
12.3.2.4. Strategic initiatives
12.3.3. Criterium, Inc.
12.3.3.1. Company overview
12.3.3.2. Financial performance
12.3.3.3. Product benchmarking
12.3.3.4. Strategic initiatives
12.3.4. ICON plc
12.3.4.1. Company overview
12.3.4.2. Financial performance
12.3.4.3. Product benchmarking
12.3.4.4. Strategic initiatives
12.3.5. Parexel International Corporation, Inc.
12.3.5.1. Company overview
12.3.5.2. Financial performance
12.3.5.3. Product benchmarking
12.3.5.4. Strategic initiatives
12.3.6. Global Pharma Consultancy AB
12.3.6.1. Company overview
12.3.6.2. Financial performance
12.3.6.3. Product benchmarking
12.3.6.4. Strategic initiatives
12.3.7. Freyr
12.3.7.1. Company overview
12.3.7.2. Financial performance
12.3.7.3. Product benchmarking
12.3.7.4. Strategic initiatives
12.3.8. Charles River Laboratories
12.3.8.1. Company overview
12.3.8.2. Financial performance
12.3.8.3. Product benchmarking
12.3.8.4. Strategic initiatives
12.3.9. Accell Clinical Research LLC
12.3.9.1. Company overview
12.3.9.2. Financial performance
12.3.9.3. Product benchmarking
12.3.9.4. Strategic initiatives
12.3.10. Regsmart Lifesciences AB
12.3.10.1. Company overview
12.3.10.2. Financial performance
12.3.10.3. Product benchmarking
12.3.10.4. Strategic initiatives
12.3.11. PHARMALEX GMBH
12.3.11.1. Company overview
12.3.11.2. Financial performance
12.3.11.3. Product benchmarking
12.3.11.4. Strategic initiatives
12.3.12. Pharmexon
12.3.12.1. Company overview
12.3.12.2. Financial performance
12.3.12.3. Product benchmarking
12.3.12.4. Strategic initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Nordic Regulatory Affairs, by Services, 2018-2030 (USD Million)
Table 4 Nordic Regulatory Affairs, by Category, 2018-2030 (USD Million)
Table 5 Nordic Regulatory Affairs, by Indication, 2018-2030 (USD Million)
Table 6 Nordic Regulatory Affairs, by Product Stage, 2018-2030 (USD Million)
Table 7 Nordic Regulatory Affairs, by Type, 2018-2030 (USD Million)
Table 8 Nordic Regulatory Affairs, by Company Size, 2018-2030 (USD Million)
Table 9 Nordic Regulatory Affairs, by End-Use, 2018-2030 (USD Million)
Table 10 Nordic Regulatory Affairs, by Region, 2018-2030 (USD Million)
Table 11 Denmark Regulatory Affairs, by Services, 2018-2030 (USD Million)
Table 12 Denmark Regulatory Affairs, by Category, 2018-2030 (USD Million)
Table 13 Denmark Regulatory Affairs, by Indication, 2018-2030 (USD Million)
Table 14 Denmark Regulatory Affairs, by Product Stage, 2018-2030 (USD Million)
Table 15 Denmark Regulatory Affairs, by Type, 2018-2030 (USD Million)
Table 16 Denmark Regulatory Affairs, by Company Size, 2018-2030 (USD Million)
Table 17 Denmark Regulatory Affairs, by End-Use, 2018-2030 (USD Million)
Table 18 Norway Regulatory Affairs, by Services, 2018-2030 (USD Million)
Table 19 Norway Regulatory Affairs, by Category, 2018-2030 (USD Million)
Table 20 Norway Regulatory Affairs, by Indication, 2018-2030 (USD Million)
Table 21 Norway Regulatory Affairs, by Product Stage, 2018-2030 (USD Million)
Table 22 Norway Regulatory Affairs, by Type, 2018-2030 (USD Million)
Table 23 Norway Regulatory Affairs, by Company Size, 2018-2030 (USD Million)
Table 24 Norway Regulatory Affairs, by End-Use, 2018-2030 (USD Million)
Table 25 Finland Regulatory Affairs, by Services, 2018-2030 (USD Million)
Table 26 Finland Regulatory Affairs, by Category, 2018-2030 (USD Million)
Table 27 Finland Regulatory Affairs, by Indication, 2018-2030 (USD Million)
Table 28 Finland Regulatory Affairs, by Product Stage, 2018-2030 (USD Million)
Table 29 Finland Regulatory Affairs, by Type, 2018-2030 (USD Million)
Table 30 Finland Regulatory Affairs, by Company Size, 2018-2030 (USD Million)
Table 31 Finland Regulatory Affairs, by End-Use, 2018-2030 (USD Million)
Table 32 Iceland Regulatory Affairs, by Services, 2018-2030 (USD Million)
Table 33 Iceland Regulatory Affairs, by Category, 2018-2030 (USD Million)
Table 34 Iceland Regulatory Affairs, by Indication, 2018-2030 (USD Million)
Table 35 Iceland Regulatory Affairs, by Product Stage, 2018-2030 (USD Million)
Table 36 Iceland Regulatory Affairs, by Type, 2018-2030 (USD Million)
Table 37 Iceland Regulatory Affairs, by Company Size, 2018-2030 (USD Million)
Table 38 Iceland Regulatory Affairs, by End-Use, 2018-2030 (USD Million)
Table 39 Sweden Regulatory Affairs, by Services, 2018-2030 (USD Million)
Table 40 Sweden Regulatory Affairs, by Category, 2018-2030 (USD Million)
Table 41 Sweden Regulatory Affairs, by Indication, 2018-2030 (USD Million)
Table 42 Sweden Regulatory Affairs, by Product Stage, 2018-2030 (USD Million)
Table 43 Sweden Regulatory Affairs, by Type, 2018-2030 (USD Million)
Table 44 Sweden Regulatory Affairs, by Company Size, 2018-2030 (USD Million)
Table 45 Sweden Regulatory Affairs, by End-Use, 2018-2030 (USD Million)
List of Figures
Figure 1 Regulatory Affairs Market segmentation
Figure 2 Data analysis models
Figure 3 Market formulation and validation
Figure 4 Data validating & publishing
Figure 5 Market research process
Figure 6 Information procurement
Figure 7 Primary research
Figure 8 Value-chain-based sizing & forecasting
Figure 9 QFD modelling for market share assessment
Figure 10 Market formulation & validation
Figure 11 Commodity flow analysis
Figure 12 Market outlook
Figure 13 Segment snapshot 1
Figure 14 Segment snapshot 2
Figure 15 Competitive landscape snapshot
Figure 16 Market trends & outlook
Figure 17 Porter’s five force analysis
Figure 18 PESTEL analysis
Figure 19 Regulatory Affairs Market: Services outlook key takeaways
Figure 20 Regulatory Affairs Market: Services movement analysis
Figure 21 Regulatory consulting market estimates and forecasts, 2018-2030 (USD Million)
Figure 22 Legal representation market estimates and forecasts, 2018-2030 (USD Million)
Figure 23 Regulatory writing & publishing market estimates and forecasts, 2018-2030 (USD Million)
Figure 24 Writing market estimates and forecasts, 2018-2030 (USD Million)
Figure 25 Publishing market estimates and forecasts, 2018-2030 (USD Million)
Figure 26 Product registration & clinical trial applications market estimates and forecasts, 2018-2030 (USD Million)
Figure 27 Other services market estimates and forecasts, 2018-2030 (USD Million)
Figure 28 Regulatory Affairs Market: Category outlook key takeaways
Figure 29 Regulatory Affairs Market: Category movement analysis
Figure 30 Drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 31 Innovators drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 32 Preclinical innovator drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 33 Clinical innovator drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 34 Pre-Market Approval (PMA) innovator drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 35 Generic drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 36 Preclinical generic drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 37 Clinical generic drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 38 Pre-Market Approval (PMA) generic drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 39 Biologics market estimates and forecasts, 2018-2030 (USD Million)
Figure 40 Biotech market estimates and forecasts, 2018-2030 (USD Million)
Figure 41 Preclinical biotech market estimates and forecasts, 2018-2030 (USD Million)
Figure 42 Clinical biotech market estimates and forecasts, 2018-2030 (USD Million)
Figure 43 Pre-Market Approval (PMA) biotech market estimates and forecasts, 2018-2030 (USD Million)
Figure 44 ATMP market estimates and forecasts, 2018-2030 (USD Million)
Figure 45 Preclinical ATMP market estimates and forecasts, 2018-2030 (USD Million)
Figure 46 Clinical ATMP market estimates and forecasts, 2018-2030 (USD Million)
Figure 47 Pre-Market Approval (PMA) ATMP market estimates and forecasts, 2018-2030 (USD Million)
Figure 48 Biosimilars market estimates and forecasts, 2018-2030 (USD Million)
Figure 49 Preclinical biosimilars market estimates and forecasts, 2018-2030 (USD Million)
Figure 50 Clinical biosimilars market estimates and forecasts, 2018-2030 (USD Million)
Figure 51 Pre-Market Approval (PMA) biosimilars market estimates and forecasts, 2018-2030 (USD Million)
Figure 52 Medical Devices market estimates and forecasts, 2018-2030 (USD Million)
Figure 53 Diagnostics market estimates and forecasts, 2018-2030 (USD Million)
Figure 54 Preclinical diagnostics market estimates and forecasts, 2018-2030 (USD Million)
Figure 55 Clinical diagnostics market estimates and forecasts, 2018-2030 (USD Million)
Figure 56 Pre-Market Approval (PMA) diagnostics market estimates and forecasts, 2018-2030 (USD Million)
Figure 57 Therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 58 Preclinical therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 59 Clinical therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 60 Pre-Market Approval (PMA) therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Figure 61 Regulatory affairs market: Indication outlook key takeaways
Figure 62 Regulatory affairs market: Indication movement analysis
Figure 63 Oncology market estimates and forecasts, 2018-2030 (USD Million)
Figure 64 Neurology market estimates and forecasts, 2018-2030 (USD Million)
Figure 65 Cardiology companies market estimates and forecasts, 2018-2030 (USD Million)
Figure 66 Immunology market estimates and forecasts, 2018-2030 (USD Million)
Figure 67 Others market estimates and forecasts, 2018-2030 (USD Million)
Figure 68 Regulatory affairs market: Product stage outlook key takeaways
Figure 69 Regulatory affairs market: Product stage movement analysis
Figure 70 Preclinical market estimates and forecasts, 2018-2030 (USD Million)
Figure 71 Clinical studies market estimates and forecasts, 2018-2030 (USD Million)
Figure 72 PMA companies market estimates and forecasts, 2018-2030 (USD Million)
Figure 73 Immunology market estimates and forecasts, 2018-2030 (USD Million)
Figure 74 Regulatory affairs market: Type outlook key takeaways
Figure 75 Regulatory affairs market: Type movement analysis
Figure 76 In-house market estimates and forecasts, 2018-2030 (USD Million)
Figure 77 Outsourced market estimates and forecasts, 2018-2030 (USD Million)
Figure 78 Regulatory affairs market: Company size outlook key takeaways
Figure 79 Regulatory affairs market: Company size movement analysis
Figure 80 Small market estimates and forecasts, 2018-2030 (USD Million)
Figure 81 Medium market estimates and forecasts, 2018-2030 (USD Million)
Figure 82 Large market estimates and forecasts, 2018-2030 (USD Million)
Figure 83 Regulatory affairs market: End-use outlook key takeaways
Figure 84 Regulatory affairs market: End-use movement analysis
Figure 85 Medical device companies market estimates and forecasts, 2018-2030 (USD Million)
Figure 86 Pharmaceutical companies market estimates and forecasts, 2018-2030 (USD Million)
Figure 87 Biotechnology companies market estimates and forecasts, 2018-2030 (USD Million)
Figure 88 Country outlook, 2024 & 2030 (USD Million)
Figure 89 Country marketplace: Key takeaways
Figure 90 Key country dynamics
Figure 91 Denmark Regulatory Affairs Market estimates and forecasts, 2018-2030 (USD Million)
Figure 92 Key country dynamics
Figure 93 Sweden Regulatory Affairs Market estimates and forecasts, 2018-2030 (USD Million)
Figure 94 Key country dynamics
Figure 95 Norway Regulatory Affairs Market estimates and forecasts, 2018-2030 (USD Million)
Figure 96 Key country dynamics
Figure 97 Finland regulatory affairs market estimates and forecasts, 2018-2030 (USD Million)
Figure 98 Key country dynamics
Figure 99 Iceland Regulatory Affairs Market estimates and forecasts, 2018-2030 (USD Million)
Figure 100 Market participant categorization
Figure 101 Regulatory affairs market share/assessment analysis, 2024
Figure 102 Strategic framework

Companies Mentioned

The major companies profiled in this Nordic Regulatory Affairs market report include:
  • Pharma Assist Sweden AB
  • Genpact
  • Criterium, Inc.
  • ICON plc
  • Parexel International Corporation, Inc.
  • Global Pharma Consultancy AB
  • Freyr
  • Charles River Laboratories
  • Accell Clinical Research LLC
  • Regsmart Lifesciences AB
  • PHARMALEX GMBH
  • Pharmexon

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedFebruary 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 586.3 Million
Forecasted Market Value ( USD ) by 2030 $ 890.7 Million
Compound Annual Growth Rate7.2%
Regions CoveredDenmark, Finland, Iceland, Norway, Sweden
No. of Companies Mentioned13

Related Topics

Related Reports

2024 Global Forecast for Regulatory Affairs Market (2025-2030 Outlook)-High Tech & Emerging Markets Report - Product Image

2024 Global Forecast for Regulatory Affairs Market (2025-2030 Outlook)-High Tech & Emerging Markets Report

  • Report
  • 132 Pages
  • Global
From
Medical Device Contract Research Organization Market Size, Share & Trends Analysis Report by Phase (Preclinical, Clinical), Service, Device Type, Region, and Segment Forecasts, 2024-2030 - Product Image

Medical Device Contract Research Organization Market Size, Share & Trends Analysis Report by Phase (Preclinical, Clinical), Service, Device Type, Region, and Segment Forecasts, 2024-2030

  • Report
  • 183 Pages
  • Global
From
Biotechnology and Pharmaceutical Services Outsourcing Market Size, Share & Trends Analysis Report by Service (Consulting, Auditing & Assessment), End-use (Pharmaceutical Companies, Biotech Companies), Region, and Segment Forecasts, 2024-2030 - Product Image

Biotechnology and Pharmaceutical Services Outsourcing Market Size, Share & Trends Analysis Report by Service (Consulting, Auditing & Assessment), End-use (Pharmaceutical Companies, Biotech Companies), Region, and Segment Forecasts, 2024-2030

  • Report
  • 150 Pages
  • Global
From
Biotechnology & Pharmaceutical Services Outsourcing Market by Services, End-User - Global Forecast 2025-2030 - Product Image

Biotechnology & Pharmaceutical Services Outsourcing Market by Services, End-User - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Life Sciences BPO Market by Services, Application - Global Forecast 2025-2030 - Product Image

Life Sciences BPO Market by Services, Application - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.